[
    [
        {
            "time": "",
            "original_text": "西部证券维持同仁堂买入评级，2021年中报点评：收入业绩增长符合预期，药品与商业发展稳健",
            "features": {
                "keywords": [
                    "西部证券",
                    "同仁堂",
                    "买入评级",
                    "2021年中报",
                    "收入业绩增长",
                    "药品",
                    "商业发展"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "商业"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "西部证券维持同仁堂买入评级，2021年中报点评：收入业绩增长符合预期，药品与商业发展稳健",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        }
    ]
]